HemaSphere Journal
HemaSphere Podcast
HemaSphere is the official online, open access journal of the European Hematology Association (EHA). HemaSphere publishes exciting basic, translational, and clinical research in hematology. We are pleased to introduce our new podcast series where our host and guest speakers exchange ideas about select HemaSphere publications. Spend some time with us and enjoy casual and insightful discussions about hematology research. Listen to the stories behind the papers. HemaSphere is always accessible; our full range of open access publications is available at www.hemaspherejournal.com.
N'hésitez pas à visiter le site du podcast et à soutenir son créateur : www.hemaspherejournal.com
Auteur
HemaSphere Journal
Catégorie
Site du podcast
Dernier épisode
16 nov. 2026
Où écouter ?
Les podcasts dans l'appli Replaio Radio Bientôt disponibleLes podcasts arrivent très bientôt dans l'appli. Installe-la dès maintenant et découvre en avant-première une toute nouvelle façon de vivre les podcasts
Épisodes
1 of 2: The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children - Ep 1.6 04.10.2023 27:29
Though many advances have been made in neutropenias, diagnosis and management are still based on physicians’ experience or local practices. Prof Francesca Fioredda and Prof Helen Papadaki, two co-authors of the HemaSphere published article The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet...
Part 1 - Comprehensive Diagnosis and Management of POEMS Syndrome - Ep 1.4 06.09.2023 23:23
POEMS syndrome (Polyneuropathy Organomegaly, Endocrinopathy, M-protein and Skin changes) is rare, and systemic manifestations are commonly overlooked initially. Diagnosis is often delayed 12-16 months, during which patients can be severely disabled. No established treatment guidelines exist for POEMS. A recent HemaSphere published article, Comprehensive Diagnosis and Management of POEMS Syndrome ,...
Part 2 - Comprehensive Diagnosis and Management of POEMS Syndrome - Ep 1.5 06.09.2023 24:32
POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, M-protein and Skin changes) is rare, and systemic manifestations are commonly overlooked initially. Diagnosis is often delayed 12-16 months, during which patients can be severely disabled. No established treatment guidelines exist for POEMS. A recent HemaSphere published article Comprehensive Diagnosis and Management of POEMS Syndrome o...
Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis - Ep 1.3 02.08.2023 34:01
Machine Learning is a subsection in the field of Artificial Intelligence. How can this be used as a tool in hematology-oncology for advanced disease prognostification and beyond? Adrián Mosquera-Orgueira and Juan Carlos Hernández-Boluda, two co-authors of the HemaSphere published article Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofib...
EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer - Ep 1.2 06.07.2023 24:32
As the overall cancer death rate has declined over past decades and cancer survival has increased, unforeseen challenges are emerging. Thrombocytopenia, often associated with cancer disease or anticancer therapy, will be more present in thrombotic cancer patients, but evidence on how to treat these patients is lacking. Prof Anna Falanga discusses these Guidelines with host Dr Stephen Hibbs in this...
Long COVID-19” of Researchers: What to Do Next? - Ep 1.1 08.06.2023 20:07
What to do next for “Long COVID-19” of researchers? A survey from scientists to scientists led by the Young European Hematology Association (Young EHA)committee led to this discussion about how COVID-19 impacted researchers, especially earlier in their career and without a network. What tools did they discover to get through it? Find it on the HemaSphere website, “Long COVID-19” of Researcher...
Podcasts similaires
Replaio n'est pas éditeur de podcasts ; les noms des émissions, les visuels et l'audio appartiennent à leurs auteurs et sont diffusés via des flux RSS publics